Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
A Phase 1b Study of Duvelisib Administered in Combination With Obinutuzumab in Patients With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) (SYNCHRONY)
Sponsor: SecuraBio
Terminated
The scope of the program has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.
Other terminated trials from SecuraBio
Other Lymphocytic Leukemia, Chronic trials with similar outcome
This PHASE1 trial investigates Lymphocytic Leukemia, Chronic and Lymphoma, Small Lymphocytic and is currently terminated or withdrawn. SecuraBio leads this study, which shows 13 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Mar 2023 — Jul 2024 [monthly]
Terminated PHASE1
-
Dec 2021 — Mar 2023 [monthly]
Terminated PHASE1
-
Apr 2021 — Dec 2021 [monthly]
Terminated PHASE1
▶ Show 8 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Terminated PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE1
-
Nov 2018 — Nov 2020 [monthly]
Terminated PHASE1
-
Jun 2018 — Nov 2018 [monthly]
Terminated PHASE1
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE1
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE1
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- SecuraBio
For direct contact, visit the study record on ClinicalTrials.gov .